The Jefferson Stem Cell Biology and Regenerative Medicine Center, Department of Stem Cell Biology & Regenerative Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Cell Cycle. 2012 Nov 1;11(21):3972-82. doi: 10.4161/cc.22227. Epub 2012 Oct 9.
Here, we identified the milk protein α-casein as a novel suppressor of tumor growth and metastasis. Briefly, Met-1 mammary tumor cells expressing α-casein showed a ~5-fold reduction in tumor growth and a near 10-fold decrease in experimental metastasis. To identify the molecular mechanism(s), we performed genome-wide transcriptional profiling. Interestingly, our results show that α-casein upregulates gene transcripts associated with interferon/STAT1 signaling and downregulates genes associated with "stemness." These findings were validated by immunoblot and FACS analysis, which showed the upregulation and hyperactivation of STAT1 and a decrease in the number of CD44(+) "cancer stem cells." These gene signatures were also able to predict clinical outcome in human breast cancer patients. Thus, we conclude that a lactation-based therapeutic strategy using recombinant α-casein would provide a more natural and non-toxic approach to the development of novel anticancer therapies.
在这里,我们发现牛奶蛋白α-酪蛋白是一种新型的肿瘤生长和转移抑制剂。简而言之,表达α-酪蛋白的 Met-1 乳腺肿瘤细胞的肿瘤生长减少了约 5 倍,实验性转移减少了近 10 倍。为了确定分子机制,我们进行了全基因组转录谱分析。有趣的是,我们的结果表明,α-酪蛋白上调了与干扰素/STAT1 信号相关的基因转录本,并下调了与“干性”相关的基因。免疫印迹和 FACS 分析验证了这些发现,表明 STAT1 的上调和过度激活以及 CD44(+)“癌症干细胞”数量的减少。这些基因特征也能够预测人类乳腺癌患者的临床结局。因此,我们得出结论,使用重组α-酪蛋白的基于哺乳的治疗策略将为开发新型抗癌疗法提供一种更自然、无毒的方法。